Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Long-Term Deferred Tax (2021 - 2022)

Historic Long-Term Deferred Tax for Pasithea Therapeutics (KTTA) over the last 2 years, with Q4 2022 value amounting to $4.2 million.

  • Pasithea Therapeutics' Long-Term Deferred Tax rose 34629.43% to $4.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.2 million, marking a year-over-year increase of 34629.43%. This contributed to the annual value of $4.2 million for FY2022, which is 34629.43% up from last year.
  • According to the latest figures from Q4 2022, Pasithea Therapeutics' Long-Term Deferred Tax is $4.2 million, which was up 34629.43% from $931000.0 recorded in Q4 2021.
  • Pasithea Therapeutics' 5-year Long-Term Deferred Tax high stood at $4.2 million for Q4 2022, and its period low was $931000.0 during Q4 2021.